NCT05214911View on ClinicalTrials.gov

Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

March 23, 2025

Study Completion Date

March 23, 2025

Conditions
Allergic Rhinitis
Interventions
DRUG

Desloratadine , Prednisolone

FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA

DRUG

Desloratadine

Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)

Trial Locations (1)

Unknown

Eurofarma Laboratorios S.A, São Paulo

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY

NCT05214911 - Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children | Biotech Hunter | Biotech Hunter